Treatment and outcomes of patients with chronic lung disease and acute myocardial infarction: Insights from the nationwide AMIS plus registry.
acute coronary syndromes
acute myocardial infarction
antithrombotic treatment
chronic lung disease
percutaneous coronary intervention
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
revised:
25
02
2024
received:
12
11
2023
accepted:
25
02
2024
medline:
14
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
aheadofprint
Résumé
Limited data are available on patients with chronic lung disease (CLD) presenting with acute myocardial infarction (AMI). We aimed to analyse baseline characteristics, treatment and outcome of those patients enrolled in the Swiss nationwide prospective AMIS Plus registry. All AMI patients enrolled between January 2002 and December 2021 with data on CLD, as defined in the Charlson Comorbidity Index, were included. The primary endpoints were in-hospital mortality and major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, reinfarction and cerebrovascular events. Baseline characteristics, in-hospital treatments and outcomes were analysed using descriptive statistics and logistic regression. Among 53,680 AMI patients enrolled during this time, 5.8% had CLD. Compared with patients without CLD, CLD patients presented more frequently with non-ST-elevation myocardial infarction (MI) and type 2 MI (12.8% vs. 6.5%, p < 0.001). With respect to treatment, CLD patients were less likely to receive P2Y12 inhibitors (p < 0.001) and less likely to undergo percutaneous coronary interventions (68.7% vs. 82.5%; p < 0.001). In-hospital mortality declined in AMI patients with CLD over time (from 12% in 2002 to 7.3% in 2021). Multivariable regression analysis showed that CLD was an independent predictor for MACCE (adjusted OR was 1.28 [95% CI 1.07-1.52], p = 0.006). Patients with CLD and AMI were less likely to receive evidence-based pharmacologic treatments, coronary revascularization and had a higher incidence of MACCE during their hospital stay compared to those without CLD. Over 20 years, in-hospital mortality was significantly reduced in AMI patients, especially in those with CLD.
Sections du résumé
BACKGROUND
BACKGROUND
Limited data are available on patients with chronic lung disease (CLD) presenting with acute myocardial infarction (AMI). We aimed to analyse baseline characteristics, treatment and outcome of those patients enrolled in the Swiss nationwide prospective AMIS Plus registry.
METHODS
METHODS
All AMI patients enrolled between January 2002 and December 2021 with data on CLD, as defined in the Charlson Comorbidity Index, were included. The primary endpoints were in-hospital mortality and major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, reinfarction and cerebrovascular events. Baseline characteristics, in-hospital treatments and outcomes were analysed using descriptive statistics and logistic regression.
RESULTS
RESULTS
Among 53,680 AMI patients enrolled during this time, 5.8% had CLD. Compared with patients without CLD, CLD patients presented more frequently with non-ST-elevation myocardial infarction (MI) and type 2 MI (12.8% vs. 6.5%, p < 0.001). With respect to treatment, CLD patients were less likely to receive P2Y12 inhibitors (p < 0.001) and less likely to undergo percutaneous coronary interventions (68.7% vs. 82.5%; p < 0.001). In-hospital mortality declined in AMI patients with CLD over time (from 12% in 2002 to 7.3% in 2021). Multivariable regression analysis showed that CLD was an independent predictor for MACCE (adjusted OR was 1.28 [95% CI 1.07-1.52], p = 0.006).
CONCLUSION
CONCLUSIONS
Patients with CLD and AMI were less likely to receive evidence-based pharmacologic treatments, coronary revascularization and had a higher incidence of MACCE during their hospital stay compared to those without CLD. Over 20 years, in-hospital mortality was significantly reduced in AMI patients, especially in those with CLD.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14193Informations de copyright
© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
World Health Organization. WHO - the top 10 causes of death. WHO. 2020; https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
Lee SN, Choi IJ, Lim S, et al. Effects of smoking on long-term clinical outcomes and lung cancer in patients with acute myocardial infarction. Korean Circ J. 2021;51(4):336-348.
Huang X, Mu X, Deng L, et al. The etiologic origins for chronic obstructive pulmonary disease. Int J COPD. 2019;14:1139-1158. doi:10.2147/COPD.S203215
Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 2010;7(3):1-4. www.plosmedicine.org
Sin DD, Paul Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514-1519.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-2264. doi:10.1016/j.jacc.2018.08.1038
Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-1737.
Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376-1384. https://pubmed.ncbi.nlm.nih.gov/23791463/
Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in older adults with cardiovascular disease. J Am Coll Cardiol. 2018;71(19):2149-2161.
Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish Nationwide study of 7.4 million individuals. Eur Heart J. 2022;32(19):2365-2375. https://academic.oup.com/eurheartj/article/32/19/2365/486058
Enriquez JR, De Lemos JA, Parikh SV, et al. Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. Am Heart J. 2013;165(1):43-49.
Dziewierz A, Siudak Z, Rakowski T, et al. Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction. Kardiol Pol. 2010;68(3):294-301.
Maeder MT. Comorbidities in patients with acute coronary syndrome: rare and negligible in trials but common and crucial in the real world. Heart 2014. 2022;100(4):268-270. Available from: https://pubmed.ncbi.nlm.nih.gov/24270747/
Fehr N, Witassek F, Radovanovic D, Erne P, Puhan M, Rickli H. Antidepressant prescription in acute myocardial infarction is associated with increased mortality 1 year after discharge. Eur J Intern Med. 2019;61:75-80. Available from: https://pubmed.ncbi.nlm.nih.gov/30704672/
Radovanovic D, Erne P, Urban P, Bertel O, Rickli H, Gaspoz JM. Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20 290 patients from the AMIS plus registry. Heart. 2017;93(11):1369-1375. Available from: www.heartjnl.com
Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O. Puhan MA EPAPInvestigators. Comorbidities in patients with acute coronary syndrome: rare and negligible in trials but common and crucial in the real world. Heart. 2014;100(4):288-294. 10.1136/
Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267-315. http://www.escardio.org/guidelines
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
Ryan H, Trosclair A, Gfroerer J. Adult current smoking: differences in definitions and prevalence estimates - NHIS and NSDUH, 2008. J Environ Public Health. 2012;2012:1-11.
Werns SW, Bates ER. The enduring value of Killip classification. Am Heart J. 1999;137(2):213-215.
Andell P, Koul S, Martinsson A, et al. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart. 2014;1(1):e000002.
Stefan MS, Bannuru RR, Lessard D, Gore JM, Lindenauer PK, Goldberg RJ. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study. Chest. 2012;141(6):1441-1448. Available from: www.chestpubs.orgCHEST/141/6/JUNE,2012
Garciá-Rio F, Soriano JB, Miravitlles M, et al. Impact of obesity on the clinical profile of a population-based sample with chronic obstructive pulmonary disease. PLoS One. 2014;9(8):1-10. Available from: www.plosone.org
Witassek F, Schwenkglenks M, Erne P, Radovanovic D. Impact of body mass index on mortality in swiss hospital patients with ST-elevation myocardial infarction: does an obesity paradox exist? Swiss Med Weekly. 2014;144:13986 Available from: www.smw.ch, w13986
Su TH, Chang SH, Chen PC, Chan YL. Temporal trends in treatment and outcomes of acute myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide population-based observational study. J Am Heart Assoc. 2017;6(3): Available from: http://ahajournals.org
Luz D, Paulo S. Chronic Coronary Artery Disease. Arq Bras Cardiol. 1999;72:5-38.
Huber LC, Arrigo M. Betablocker und asthma bronchiale: ja oder Nein? Cardiovasc Med. 2016;19(10):256-260.
Hadyś A. The asthma-COPD overlap syndrome. Int Rev Allergol Clin Immunol Fam Med. 2016;22(3):168-172.
Quint JK, Herrett E, Bhaskaran K, et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ (Online). 2013;347:f6650.
Wang WH, Cheng CC, Mar GY, Wei KC, Huang WC, Liu CP. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. Heart Vessels. 2019;34(7):1158-1167. https://pubmed.ncbi.nlm.nih.gov/30680495/
Su TH, Chang SH, Kuo CF, Liu PH, Chan YL. Β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide population-based observational study. PLoS One. 2019;14(3):e0213187.
Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res. 2021;22(1):64 Available from: http://www.ncbi.nlm.nih.gov/pubmed/33622362
Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1):169S-173S. Available from: www.chestjournal.org
Spanevello A, Beghé B, Visca D, Fabbri LM, Papi A. Chronic cough in adults. Eur J Intern Med. 2020;78:8-16. http://www.ejinme.com/article/S095362052030114X/fulltext
Enriquez JR, Parikh SV, Selzer F, et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest. 2011;140(3):604-610. www.chestpubs.org
Gupta S, Vaidya SR, Arora S, Bahekar A, Devarapally SR. Type 2 versus type 1 myocardial infarction: a comparison of clinical characteristics and outcomes with a meta-analysis of observational studies. Cardiovasc Diagn Ther. 2017;7(4):348-358.
Pollack CV, Amin A, Wang T, et al. Contemporary NSTEMI management: the role of the hospitalist. Hosp Pract. 2020;48(1):1-11. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=ihop20